Novartis AG (NYSE:NVS) Stock Position Raised by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC lifted its holdings in shares of Novartis AG (NYSE:NVS) by 12.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 25,134 shares of the company’s stock after buying an additional 2,700 shares during the period. EagleClaw Capital Managment LLC’s holdings in Novartis were worth $2,446,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Human Investing LLC bought a new position in Novartis in the 4th quarter worth about $25,000. Union Bancaire Privee UBP SA bought a new position in Novartis in the 4th quarter worth about $27,000. Legacy Investment Solutions LLC bought a new position in Novartis in the 3rd quarter worth about $28,000. Kestra Investment Management LLC bought a new position in Novartis in the 4th quarter worth about $47,000. Finally, Brooklyn Investment Group bought a new position in Novartis in the 4th quarter worth about $55,000. Institutional investors own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Barclays restated an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Morgan Stanley started coverage on shares of Novartis in a research report on Wednesday, February 12th. They issued an “underweight” rating for the company. UBS Group reiterated a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Finally, StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Trading Up 1.0 %

Novartis stock opened at $113.00 on Friday. The firm has a 50 day simple moving average of $103.67 and a 200-day simple moving average of $108.02. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The stock has a market capitalization of $230.97 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. As a group, equities research analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.